Attendee search 

Synpromics is a life science company focused on synthetic biology. Our core proprietary technology enables the design of optimized Synthetic Promoters to more effectively and efficiently regulate gene expression throughout biotechnology applications. Via product-development and distribution partnerships, Synpromics will commercially apply our novel promoters to enhance and expedite life science R&D, improve biology-based production processes, advance agricultural biotech and progress personalized medicine.

Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling.

Selcia drug discovery provides integrated drug discovery services to support academics, institutions, biotech and pharma companies. Selcia assist in grant applications; execute the medicinal chemistry to deliver the best drug candidates, provide supporting project management and primary pharmacology, to ensure project success.

Selcia radiolabelling specialises in 14C GMP radiolabelling and produces 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, microdosing, research and regulatory studies; and environmental fate studies.

The purity and structure of our products are assured by our internal MHRA GLP accredited analytical department with 500MHz, 400MHz & 300MHz NMRs, mass spec and separation specialists. The group are experts in problem resolution to ensure projects meet agreed milestones.

Areas of Expertise:

• Medicinal chemistry:  Small molecules, macrocycles, natural product chemistry
• Disease expertise: Anti-infectives, inflammation, CNS, pain, metabolic
• Target classes: GPCRs, ion channels, enzymes, isomerases
• 14C Custom Radiosynthesis
• GMP Radiolabelled API for Clinical Trials
• GLP/GMP Analytics – GLP NMR
• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds

www.selcia.com                               contact@selcia.com

Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity. 

Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS.  Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.

Canbex closed a $3.2m financing round led by Merck Serono Ventures in April 2013, and its lead anti-spasticity compound, VSN16R, is set to enter Phase I safety testing.  In studies to date, VSN16R shows substantially improved tolerability compared to other compounds, and is as effective against spasticity as any other agent known.

Supported by its leading London-based scientific and clinical team, Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity. 

To find out more, please meet us at the event or contact us using the details below

Canbex Therapeutics Ltd

London BioScience Innovation Centre

2 Royal College Street

London

NW1 0NH

Tel: +44 (0)207 554 5872

Email: enquiries@canbex.co.uk

Glythera is an emerging biotechnology company specializing in the development of next generation biotherapeutics through the application of its advanced proprietary conjugation and glycosylation technologies.

Located in the North East of the UK with its dedicated bioprocessing and chemistry development laboratories at Newcastle University, Glythera is positioned as a critical partner in any development program centred on its PermaLink™ and PermaCarb™ technologies.

Our PermaLink™ platform supports highly selective site specific conjugation whilst demonstrating significantly increased stability with our core focus being in the development of enhanced Antibody Drug Conjugates and bi-specifics.

Glythera’s PermaCarb™ technology allows direct substitution of endogenous glycan’s or correction of micro-heterogeneity using stable analogues to improve bioavailability and efficacy and has been demonstrated in a range of next generation biotherapeutics.

Our Mission is to enable improved clinical regimes through the creation of the next generation of safe, efficacious biotherapeutic products in oncology and therapeutic indications.

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.

Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.

MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

BioPartner is your UK point of contact at Bio-Europe 2013 based at stand #68.

BioPartner is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. Through the BioPartnership Programme, BioPartner assists companies to attend major international biopharma conferences by providing access to government grants and heavily discounted entry fees.